Cinausero et al. 17retrospectively analyzed 88 patients with locally advanced or metastatic nonsquamous NSCLC who received ICIs and found that patients with KRAS mutations had longer overall survival (OS) and PFS than patients with KRAS wild‐type, which was statistically significant. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.